IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1

Marine Karchava, Lali Sharvadze, Nikoloz Chkhartishvili, Kenrad Edwin Nelson, Nino Gochitashivli, Lana Gatserelia, Natia Dvali, Ekaterine Dolmazashvili, Lela Dzigua, Nino Badridze, Maia Zhamutashvili, Tengiz Tsertsvadze

Research output: Contribution to journalArticle

Abstract

Objectives: The early identification of factors contributing to the successful treatment of hepatitis C infection is important for researchers and clinicians. Studies carried out on the role of an ultrarapid viral response (URVR) for the prediction of a sustained viral response (SVR) have shown its high positive predictive value (PPV). However, data on the combined effect of URVR with IL28B genotypes for the prediction of SVR are lacking. Our aim was to study the role of URVR and IL28B genotypes in the prediction of SVR among patients in Georgia infected with genotype 1. Methods: Of a total of 156 patients enrolled in the study, 143 were included in the final analyses. Viral load testing for monitoring the viral response was carried out at 3, 24, 48, and 72 h and at 1, 2, and 4 weeks after the initiation of treatment. IL28B single nucleotide polymorphisms in rs12979860 were genotyped using real-time PCR methods. Results: Our study showed that URVR was the earliest treatment predictor among genotype 1 patients harboring the IL28B C/C genotype (PPV-100%). Moreover, the C/C genotype was found to have a high PPV among genotype 1 patients without URVR or a rapid viral response, unlike patients infected with genotype 2 or 3. URVR and IL28B C/C genotypes were not as predictive of an SVR among genotype 2 and 3 patients; however, rapid viral responses were highly predictive of an SVR in these patients. Conclusion: Our results suggest that testing for IL28B genotypes and viral load at weeks 1 and 2 may improve the ability to predict an SVR among hepatitis C virus genotype 1 patients; this information may be useful to ensure patient compliance with treatment.

Original languageEnglish (US)
Pages (from-to)817-823
Number of pages7
JournalEuropean Journal of Gastroenterology and Hepatology
Volume24
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Hepatitis C
Genotype
Therapeutics
Viral Load
Aptitude
Patient Compliance
Hepacivirus
Single Nucleotide Polymorphism
Real-Time Polymerase Chain Reaction
Research Personnel

Keywords

  • hepatitis C virus viral load
  • interferon treatment
  • single nucleotide polymorphisms

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1. / Karchava, Marine; Sharvadze, Lali; Chkhartishvili, Nikoloz; Nelson, Kenrad Edwin; Gochitashivli, Nino; Gatserelia, Lana; Dvali, Natia; Dolmazashvili, Ekaterine; Dzigua, Lela; Badridze, Nino; Zhamutashvili, Maia; Tsertsvadze, Tengiz.

In: European Journal of Gastroenterology and Hepatology, Vol. 24, No. 7, 07.2012, p. 817-823.

Research output: Contribution to journalArticle

Karchava, M, Sharvadze, L, Chkhartishvili, N, Nelson, KE, Gochitashivli, N, Gatserelia, L, Dvali, N, Dolmazashvili, E, Dzigua, L, Badridze, N, Zhamutashvili, M & Tsertsvadze, T 2012, 'IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1', European Journal of Gastroenterology and Hepatology, vol. 24, no. 7, pp. 817-823. https://doi.org/10.1097/MEG.0b013e328353fd11
Karchava, Marine ; Sharvadze, Lali ; Chkhartishvili, Nikoloz ; Nelson, Kenrad Edwin ; Gochitashivli, Nino ; Gatserelia, Lana ; Dvali, Natia ; Dolmazashvili, Ekaterine ; Dzigua, Lela ; Badridze, Nino ; Zhamutashvili, Maia ; Tsertsvadze, Tengiz. / IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1. In: European Journal of Gastroenterology and Hepatology. 2012 ; Vol. 24, No. 7. pp. 817-823.
@article{3ab5e3ef38da4cb5920edf7a391d7644,
title = "IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1",
abstract = "Objectives: The early identification of factors contributing to the successful treatment of hepatitis C infection is important for researchers and clinicians. Studies carried out on the role of an ultrarapid viral response (URVR) for the prediction of a sustained viral response (SVR) have shown its high positive predictive value (PPV). However, data on the combined effect of URVR with IL28B genotypes for the prediction of SVR are lacking. Our aim was to study the role of URVR and IL28B genotypes in the prediction of SVR among patients in Georgia infected with genotype 1. Methods: Of a total of 156 patients enrolled in the study, 143 were included in the final analyses. Viral load testing for monitoring the viral response was carried out at 3, 24, 48, and 72 h and at 1, 2, and 4 weeks after the initiation of treatment. IL28B single nucleotide polymorphisms in rs12979860 were genotyped using real-time PCR methods. Results: Our study showed that URVR was the earliest treatment predictor among genotype 1 patients harboring the IL28B C/C genotype (PPV-100{\%}). Moreover, the C/C genotype was found to have a high PPV among genotype 1 patients without URVR or a rapid viral response, unlike patients infected with genotype 2 or 3. URVR and IL28B C/C genotypes were not as predictive of an SVR among genotype 2 and 3 patients; however, rapid viral responses were highly predictive of an SVR in these patients. Conclusion: Our results suggest that testing for IL28B genotypes and viral load at weeks 1 and 2 may improve the ability to predict an SVR among hepatitis C virus genotype 1 patients; this information may be useful to ensure patient compliance with treatment.",
keywords = "hepatitis C virus viral load, interferon treatment, single nucleotide polymorphisms",
author = "Marine Karchava and Lali Sharvadze and Nikoloz Chkhartishvili and Nelson, {Kenrad Edwin} and Nino Gochitashivli and Lana Gatserelia and Natia Dvali and Ekaterine Dolmazashvili and Lela Dzigua and Nino Badridze and Maia Zhamutashvili and Tengiz Tsertsvadze",
year = "2012",
month = "7",
doi = "10.1097/MEG.0b013e328353fd11",
language = "English (US)",
volume = "24",
pages = "817--823",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1

AU - Karchava, Marine

AU - Sharvadze, Lali

AU - Chkhartishvili, Nikoloz

AU - Nelson, Kenrad Edwin

AU - Gochitashivli, Nino

AU - Gatserelia, Lana

AU - Dvali, Natia

AU - Dolmazashvili, Ekaterine

AU - Dzigua, Lela

AU - Badridze, Nino

AU - Zhamutashvili, Maia

AU - Tsertsvadze, Tengiz

PY - 2012/7

Y1 - 2012/7

N2 - Objectives: The early identification of factors contributing to the successful treatment of hepatitis C infection is important for researchers and clinicians. Studies carried out on the role of an ultrarapid viral response (URVR) for the prediction of a sustained viral response (SVR) have shown its high positive predictive value (PPV). However, data on the combined effect of URVR with IL28B genotypes for the prediction of SVR are lacking. Our aim was to study the role of URVR and IL28B genotypes in the prediction of SVR among patients in Georgia infected with genotype 1. Methods: Of a total of 156 patients enrolled in the study, 143 were included in the final analyses. Viral load testing for monitoring the viral response was carried out at 3, 24, 48, and 72 h and at 1, 2, and 4 weeks after the initiation of treatment. IL28B single nucleotide polymorphisms in rs12979860 were genotyped using real-time PCR methods. Results: Our study showed that URVR was the earliest treatment predictor among genotype 1 patients harboring the IL28B C/C genotype (PPV-100%). Moreover, the C/C genotype was found to have a high PPV among genotype 1 patients without URVR or a rapid viral response, unlike patients infected with genotype 2 or 3. URVR and IL28B C/C genotypes were not as predictive of an SVR among genotype 2 and 3 patients; however, rapid viral responses were highly predictive of an SVR in these patients. Conclusion: Our results suggest that testing for IL28B genotypes and viral load at weeks 1 and 2 may improve the ability to predict an SVR among hepatitis C virus genotype 1 patients; this information may be useful to ensure patient compliance with treatment.

AB - Objectives: The early identification of factors contributing to the successful treatment of hepatitis C infection is important for researchers and clinicians. Studies carried out on the role of an ultrarapid viral response (URVR) for the prediction of a sustained viral response (SVR) have shown its high positive predictive value (PPV). However, data on the combined effect of URVR with IL28B genotypes for the prediction of SVR are lacking. Our aim was to study the role of URVR and IL28B genotypes in the prediction of SVR among patients in Georgia infected with genotype 1. Methods: Of a total of 156 patients enrolled in the study, 143 were included in the final analyses. Viral load testing for monitoring the viral response was carried out at 3, 24, 48, and 72 h and at 1, 2, and 4 weeks after the initiation of treatment. IL28B single nucleotide polymorphisms in rs12979860 were genotyped using real-time PCR methods. Results: Our study showed that URVR was the earliest treatment predictor among genotype 1 patients harboring the IL28B C/C genotype (PPV-100%). Moreover, the C/C genotype was found to have a high PPV among genotype 1 patients without URVR or a rapid viral response, unlike patients infected with genotype 2 or 3. URVR and IL28B C/C genotypes were not as predictive of an SVR among genotype 2 and 3 patients; however, rapid viral responses were highly predictive of an SVR in these patients. Conclusion: Our results suggest that testing for IL28B genotypes and viral load at weeks 1 and 2 may improve the ability to predict an SVR among hepatitis C virus genotype 1 patients; this information may be useful to ensure patient compliance with treatment.

KW - hepatitis C virus viral load

KW - interferon treatment

KW - single nucleotide polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=84862223243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862223243&partnerID=8YFLogxK

U2 - 10.1097/MEG.0b013e328353fd11

DO - 10.1097/MEG.0b013e328353fd11

M3 - Article

C2 - 22569080

AN - SCOPUS:84862223243

VL - 24

SP - 817

EP - 823

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 7

ER -